Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Electrocardiographic safety of daily Hydroxychloroquine 400mg plus Azithromycin 250mg as an ambulatory treatment for COVID-19 patients in Cameroon
Mfeukeu-Kuate et al. (Preprint)
Mfeukeu-Kuate, Electrocardiographic safety of daily Hydroxychloroquine 400mg plus Azithromycin 250mg as an ambulatory.., et al. (Preprint)
Jun 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
No life-threatening modifications of the QT interval was observed in non-severe COVID-19 patients treated ambulatory with HCQ+AZ. 51 relatively young patients 39 +/- 11.
Mfeukeu-Kuate et al., 29 Jun 2020, preprint, 29 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139386; this version posted June 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . Electrocardiographic safety of daily Hydroxychloroquine 400mg plus Azithromycin 250mg as an ambulatory treatment for COVID-19 patients in Cameroon. Liliane Mfeukeu-Kuate1,2,MD; William Ngatchou3,4, MD, PhD; Mazou Ngou Temgoua2, MD; Charles Kouanfack1,5, MD, PhD; Daniel Lemogoum6,7, MD, PhD; Joel Noutakdie Tochie8, MD; Armel Zemsi1, MD; Lauriane Fomete1, MD; Skinner Lekelem8, MD; Sylvain Zemsi2, BSc; Joelle Sobngwi9, MD, PhD; Thierry Ntandzi1, MD; Christian Ngongang Ouankou5, MD; Yves Wasnyo1, MD, MPH; Antoinette Ntsama Assiga1, MD; Jan René Nkeck2, MD; Ahmadou Musa Jingi10, MD; Magellan Guewo1, PhD; Eric Walter Pefura Yone2,12, MD, PhD; Charlotte Moussi Omgba 13, MD, MPH; Paul Owono Etoundi1,8, MD; Jean Cyr Yombi14, MD; Alain Menanga2, MD; Samuel Kingue2, MD; Jacqueline Ze Minkande8, MD; Jean Claude Mbanya1,2, MD, PhD; Pierre Ongolo Zogo1,15, MD, PhD; Pierre Joseph Fouda1,8, MD; Eugène Sobngwi1,2, MD, PhD. Author affiliations 1 Central Hospital of Yaoundé, Cameroon. 2 Department of Internal Medicine and specialities, Faculty of Médicine and Biomedical Sciences of the University of Yaounde I, Cameroon. 3 Department of Surgery, University of Douala. Hypertension Clinic and Cardiac Surgery. 4 Department St Pierre Hospital, Université libre de Bruxelles, Brussels, Belgium. 5 Faculty of Medicine and Pharmaceutical Sciences of Dschang University. 6 Department of Medicine, University of Douala. 7 Hypertension Clinic and Cardiology Department. Erasme Hospital Université libre de Bruxelles, Brussels, Belgium. 8 Department of Surgery and Specialities, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Cameroon. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139386; this version posted June 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . 9 ANRS Cameroon. 10 Recherche - Santé et Développement, Yaoundé Cameroon and The London School of Economics and Political Sciences, London, UK. 11 Faculty of Health Sciences, University of Bamenda, Cameroon. 12 Jamot Hospital of Yaounde. 13 Regional Public Health Delegation for the Centre, Ministry of Public Health Cameroon. 14 Department of Infectious Diseases, Saint Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium. 15 Centre for the Development of Good Health Practices, Yaounde, Cameroon. Corresponding author : Professor Eugene Sobngwi, Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, and Yaounde Central Hospital, Cameroon sobngwieugene@yahoo.fr Word count: 1189 words, Tables 2, Figures 0 medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139386; this version posted June 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit